AstraZeneca PLC to Build $200 Million Manufacturing Plant in China Medical City
Published: Oct 10, 2011
October 10, 2011 -- AstraZeneca will spend $200 million to build a major new manufacturing facility in Taizhou’s China Medical City. The plant, which will produce both IV and solid oral medications for the China market, is the largest investment AstraZeneca has ever made in a single manufacturing site. China is becoming increasing important to AstraZeneca. In the first half of 2011, the company’s revenues in the PRC grew 22% to $624 million. More details....
Stock Symbol: (NYSE: AZN)